The involvement of RhoA and Wnt-5a in the tumorigenesis and progression of ovarian epithelial carcinoma

International Journal of Molecular Sciences

Volumn 14, Issue 12, 2013, Pages 24187-24199

  Chen, Shuo ^a   Wang, Jun ^b   Gou, Wen Feng ^a   Xiu, Ying Ling ^a   Zheng, Hua Chuan ^a   Zong, Zhi Hong ^a   Takano, Yasuo ^c   Zhao, Yang ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

^c KANAGAWA CANCER CENTER   (Japan)

Author keywords

Ovarian carcinoma; Phenotype; RhoA; Tumorigenesis and progression; Wnt 5a signaling

Indexed keywords

PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL XL; PROTEIN KINASE B; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; S6 KINASE; SURVIVIN; VASCULOTROPIN; WNT5A PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER STAGING; CARCINOGENESIS; CELL DIFFERENTIATION; CELL INVASION ASSAY; CELL VIABILITY; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; OVARY CARCINOMA; PROTEIN EXPRESSION; RADIOIMMUNOPRECIPITATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WOUND HEALING;

APOPTOSIS; CARCINOGENESIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PHENOTYPE; PROTO-ONCOGENE PROTEINS; RHOA GTP-BINDING PROTEIN; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; WNT PROTEINS;

EID: 84890409203     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms141224187     Document Type: Article

References (28)

1. Piek, J. M.; Kenemans, P.; Zweemer, R. P.; van Diest, P. J.; Verheijen, R. H. Ovarian carcinogenesis, an alternative theory. Gynecol. Oncol. 2007, 107, 355.
2. Piek, J. M.; van Diest, P. J.; Verheijen, R. H. Ovarian carcinogenesis: An alternative hypothesis. Adv. Exp. Med. Biol. 2008, 622, 79-87.
3. Yu, L.-L.; Gu, J.-Y. Advances in the role of Rho sub-family in tumor invasion. Fudan Univ. J. Med. Sci. 2010, 37, 617-619.
4. Hall, A.; Rho, G. T. Pases and the actin cytoskeleton. Science 1998, 279, 509-514.
5. Der Mardirossian, C.; Bokoch, G. M. GDIs: Central regulatory molecules in Rho GTPase activation. Trends Cell Biol. 2005, 15, 356-363.
6. Olofsson, B. Rho guanine dissociation inhibitors: Pivotal molecules in cellular signalling. Cell. Signal. 1999, 11, 545-554.
7. Liu, J.; Zhang, Y.; Xu, R.; Du, J.; Hu, Z.; Yang, L.; Chen, Y.; Zhu, Y.; Gu, L. PI3K/Akt-dependent phosphorylation of GSK3β and activation of RhoA regulate Wnt5a-induced gastric cancer cell migration. Cell. Signal. 2013, 25, 447-456.
8. Zhu, Y.; Tian, Y.; Du, J.; Hu, Z.; Yang, L.; Liu, J.; Gu, L. Dvl2-dependent activation of Daam1 and RhoA regulates Wnt5a-induced breast cancer cell migration. PLoS One 2012, 7, e37823.
9. Kikuchi, A.; Yamamoto, H.; Sato, A.; Matsumoto, S. Wnt5a: Its signalling, functions and implication in diseases. Acta Physiol. (Oxf.) 2012, 204, 17-33.
10. Ellenbroek, S. I.; Collard, J. G. Rho GTPases: Functions and association with cancer. Clin. Exp. Metastasis 2007, 24, 657-672.
11. Horiuchi, A.; Imai, T.; Wang, C.; Ohira, S.; Feng, Y.; Nikaido, T.; Konishi, I. Up-regulation of small GTPases, RhoA and RhoC, is associated with tumor progression in ovarian carcinoma. Lab. Investig. 2003, 83, 861-870.
12. Peacock, J. G.; Miller, A. L.; Bradley, W. D.; Rodriguez, O. C.; Webb, D. J.; Koleske, A. J. The Abl-related gene tyrosine kinase acts through p190RhoGAP to inhibit actomyosin contractility and regulate focal adhesion dynamics upon adhesion to fibronectin. Mol. Biol. Cell 2007, 18, 3860-3872.
13. Merajver, S. D.; Usmani, S. Z. Multifaceted role of Rho proteins in angiogenesis. J. Mammary Gland Biol. Neoplasia 2005, 10, 291-298.
14. Ip, C. K. M.; Cheung, A. N. Y.; Ngan, H. Y. S.; Wong, A. S. T. p70 S6 kinase in the control of actin cytoskeleton dynamics and directed migration of ovarian cancer cells. Oncogene 2011, 30, 2420-2432.
15. Denoyelle, C.; Albanese, P.; Uzan, G.; Hong, L.; Vannier, J. P.; Soria, J.; Soria, C. Molecular mechanism of the anti-cancer activity of cerivastatin, an inhibitor of HMG-CoA reductase, on aggressive human breast cancer cells. Cell Signal. 2003, 15, 327-338.
16. Weeraratna, A. T.; Jiang, Y.; Hostetter, G.; Rosenblatt, K.; Duray, P.; Bittner, M.; Trent, J. M. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 2002, 1, 279-288.
17. Bittner, M.; Meltzer, P.; Chen, Y.; Jiang, Y.; Seftor, E.; Hendrix, M.; Radmacher, M.; Simon, R.; Yakhini, Z.; Ben-Dor, A.; et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000, 406, 536-540.
18. Kurayoshi, M.; Oue, N.; Yamamoto, H.; Kishida, M.; Inoue, A.; Asahara, T.; Yasui, W.; Kikuchi, A. Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res. 2006, 66, 10439-10448.
19. Li, X.; Jia, Y.; Zhang, W.; Zhang, Y.; Li, B.; Huang, M; Bao, F.; Wu, J.; Lou, Y. The Research progress about Wnt pathway on lung cancer stem cells. Chin. J. Lung Cancer 2011, 14, 695-698.
20. Dejmek, J.; Dejmek, A.; Safholm, A.; Sjolander, A.; Andresson, T. Wnt-5a protein expression in primary dukes B colon cancers identifies a subgroup of patients with good prognosis. Cancer Res. 2005, 65, 9142-9146.
21. Kremenevskaja, N.; von Wasielewski, R.; Rao, A. S.; Schöfl, C.; Andersson, T.; Brabant, G. Wnt-5a has tumor suppressor activity in thyroid carcinoma. Oncogene 2005, 24, 2144-2154.
22. Veeman, M. T.; Axelrod, J. D.; Moon, R. T. A second canon: Functions and mechanisms of β-catenin-independent Wnt signaling. Dev. Cell 2003, 5, 367-377.
23. Kurayoshi, M.; Yamamoto, H.; Izumi, S.; Kikuchi, A. Post-translational palmitoylation and glycosylation of Wnt-5a are necessary for its signaling. Biochem. J. 2007, 402, 515-523.
24. Kikuchi, A.; Yamamoto, H. Tumor formation due to abnormalities in the β-catenin-independent pathway of Wnt signaling. Cancer Sci. 2008, 99, 202-208.
25. Peng, C.; Zhang, X.; Yu, H.; Wu, D.; Zheng, J. Wnt5a as a predictor in poor clinical outcome of patients and a mediator in chemoresistance of ovarian cancer. Int. J. Gynecol. Cancer 2011, 21, 280-288.
26. Badiglian, F. L.; Oshima, C. T.; de Oliveira Lima, F.; de Oliveira Costa, H.; de Sousa Damião, R.; Gomes, T. S.; Gonçalves, W. J. Canonical and noncanonical Wnt pathway: A comparison among normal ovary, benign ovarian tumor and ovarian cancer. Oncol. Rep. 2009, 21, 313-320.
27. Strutt, D.; Weber, U.; Mlodzik, M. The role of RhoA in tissue polarity and Frizzled signalling. Nature 1997, 387, 292-295.
28. Qian, D.; Jones, C.; Rzadzinska, A.; Mark, S.; Zhang, X.; Steel, K. P.; Dai, X.; Chen, P. Wnt5a functions in planar cell polarity regulation in mice. Dev. Biol. 2007, 306, 121-133.